LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article: Cemiplimab as First Line Therapy in Advanced Penile Squamous Cell Carcinoma: A Real-World Experience.

    Rouvinov, Keren / Mazor, Gal / Kozlener, Ella / Meirovitz, Amichay / Shrem, Noa Shani / Abu Saleh, Omar / Shalata, Sondos / Yakobson, Alexander / Shalata, Walid

    Journal of personalized medicine

    2023  Volume 13, Issue 11

    Abstract: In the treatment of cancer, immune checkpoint inhibitors (ICIs) have demonstrated significantly greater effectiveness compared to conventional cytotoxic or platinum-based chemotherapies. To assess the efficacy of ICI's in penile squamous cell carcinoma ( ... ...

    Abstract In the treatment of cancer, immune checkpoint inhibitors (ICIs) have demonstrated significantly greater effectiveness compared to conventional cytotoxic or platinum-based chemotherapies. To assess the efficacy of ICI's in penile squamous cell carcinoma (pSCC) we performed a retrospective observational study. We reviewed electronic medical records of patients with penile squamous cell carcinoma (SCC), diagnosed between January 2020 and February 2023. Nine patients were screened, of whom three were ineligible for chemotherapy and received immunotherapy, cemiplimab, in a first-line setting. Each of the three immunotherapy-treated patients achieved almost a complete response (CR) after only a few cycles of therapy. The first patient had cerebral arteritis during treatment and received a high-dose steroid treatment with resolution of the symptoms of arteritis. After tapering down the steroids dose, the patient continued cemiplimab without further toxicity. The other two patients did not have any toxic side effects of the treatment. To the best of our knowledge, this is the first real world report of near CR with cemiplimab as a first-line treatment in penile SCC.
    Language English
    Publishing date 2023-11-20
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662248-8
    ISSN 2075-4426
    ISSN 2075-4426
    DOI 10.3390/jpm13111623
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castration-sensitive prostate cancer.

    Mahler, Mary / Al-Ezzi, Esmail / Shrem, Noa Shani / Zhang, Liying / Winquist, Eric / Canil, Christina / Ong, Michael / Hansen, Aaron R / Emmenegger, Urban

    Urologic oncology

    2022  Volume 40, Issue 12, Page(s) 539.e17–539.e22

    Abstract: Objective: To assess the effectiveness of docetaxel rechallenge (DR) for metastatic castration-resistant prostate cancer (mCRPC) following chemohormonal therapy for metastatic castrate-sensitive prostate cancer (mCSPC). Additionally, we sought to define ...

    Abstract Objective: To assess the effectiveness of docetaxel rechallenge (DR) for metastatic castration-resistant prostate cancer (mCRPC) following chemohormonal therapy for metastatic castrate-sensitive prostate cancer (mCSPC). Additionally, we sought to define clinical factors predicting treatment response.
    Patients and methods: Retrospective analysis of men treated with docetaxel for mCSPC and then rechallenged in the mCRPC setting from four cancer centers in Ontario, Canada. Prostate specific antigen (PSA) response, progression-free survival (PFS), and overall survival (OS) following DR were evaluated.
    Results: Fifty five patients were identified between 2015 and 2020. Prior to DR, 94.5% of patients received androgen-receptor axis targeted therapy, 20% received radium-223, and 1.8% received cabazitaxel. Among 54 evaluable patients, 27.8% had a PSA decline ≥50%. Median PFS was 4.1 months (95% CI, 2.1-4.8) and median OS from androgen deprivation therapy initiation was 38.3 months (95% CI, 32.9-41.0). A Gleason Score of ≥8 was an independent predictor of prolonged PFS (HR 0.32, 95% CI, 0.12-0.81; P=0.02).
    Conclusions: DR following chemohormonal therapy for mCSPC produced a meaningful PSA response in approximately one-quarter of patients, with relatively short PFS. The impact of Gleason Score on docetaxel response warrants further investigation.
    MeSH term(s) Male ; Humans ; Docetaxel/therapeutic use ; Prostate-Specific Antigen ; Prostatic Neoplasms, Castration-Resistant/pathology ; Androgen Antagonists/therapeutic use ; Retrospective Studies ; Androgens ; Castration ; Ontario ; Treatment Outcome ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
    Chemical Substances Docetaxel (15H5577CQD) ; Prostate-Specific Antigen (EC 3.4.21.77) ; Androgen Antagonists ; Androgens
    Language English
    Publishing date 2022-10-20
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1336505-8
    ISSN 1873-2496 ; 1078-1439
    ISSN (online) 1873-2496
    ISSN 1078-1439
    DOI 10.1016/j.urolonc.2022.09.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4817: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Increased Incidence of Lung Cancer Among Patients With Superficial Transitional Cell Carcinoma: A Potential Risk Cohort for Lung Cancer Screening.

    Tolwin, Yaakov / Gillis, Roni / Agmon, Inbar Nardi / Shrem, Noa Shani / Rosenbaum, Eli / Peled, Nir

    Clinical lung cancer

    2019  Volume 20, Issue 6, Page(s) 429–434

    Abstract: Background: Smoking is a major risk factor for lung cancer (LC) and transitional cell carcinoma of the bladder (TCC). Current recommendations for LC screening do not include TCC as a risk factor for determining screening eligibility. In this study we ... ...

    Abstract Background: Smoking is a major risk factor for lung cancer (LC) and transitional cell carcinoma of the bladder (TCC). Current recommendations for LC screening do not include TCC as a risk factor for determining screening eligibility. In this study we aimed to evaluate whether TCC patients constitute a population who might benefit from LC screening.
    Patients and methods: The Surveillance, Epidemiology, and End Results 18 database was used to determine the incidence, standardized incidence ratio (SIR), and the average time to diagnosis of LC in patients with localized TCC of the bladder (American Joint Committee on Cancer, sixth edition, stages 0-1).
    Results: On the basis of 91,606 patients with localized TCC, The SIR for LC in men was 1.89 (95% confidence interval [CI], 1.8-1.97), significantly different from the risk for all solid tumors. The SIR for LC in women was 2.43 (95% CI, 2.22-2.65), significantly higher than for men. The 5-year incidence of LC was 3.2%, and the 10-year incidence was 5.94%. The average time to diagnosis of LC was 3.4 years, with >80% of LC cases occurring within 5 years of TCC diagnosis.
    Conclusion: Patients with localized TCC have a higher incidence of LC than the general population. The risk is significantly increased among women compared with men. Considering this increased risk, patients with early stage TCC might stand to benefit from LC screening. Additional differences were noted between male and female TCC patients, which bear further study.
    MeSH term(s) Adolescent ; Adult ; Aged ; Aged, 80 and over ; Carcinoma, Transitional Cell/diagnosis ; Carcinoma, Transitional Cell/epidemiology ; Child ; Child, Preschool ; Cohort Studies ; Early Detection of Cancer ; Female ; Humans ; Incidence ; Infant ; Infant, Newborn ; Israel/epidemiology ; Lung/diagnostic imaging ; Lung Neoplasms/diagnosis ; Lung Neoplasms/epidemiology ; Male ; Middle Aged ; Neoplasms, Multiple Primary/epidemiology ; Risk ; Sex Factors ; Smoking/adverse effects ; Urinary Bladder Neoplasms/diagnosis ; Urinary Bladder Neoplasms/epidemiology ; Young Adult
    Language English
    Publishing date 2019-06-18
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2145146-1
    ISSN 1938-0690 ; 1525-7304
    ISSN (online) 1938-0690
    ISSN 1525-7304
    DOI 10.1016/j.cllc.2019.06.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5893: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 440: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis.

    Rouvinov, Keren / Levanon, Eran / Peer, Avivit / Sarfaty, Michal / Sarid, David / Neiman, Victoria / Grikshtas, Eduard / Rosenbaum, Eli / Kushnir, Igal / Talmor, Barak / Friger, Michael / Zarbiv, Yonaton / Gez, Eli / Dresler, Hadas / Shalata, Walid / Meirovitz, Amichay / Shrem, Noa Shani / Yakobson, Alexander / Mermershtain, Wilmosh /
    Keizman, Daniel

    Frontiers in oncology

    2023  Volume 13, Page(s) 1151701

    Abstract: Background: Erdafitinib, a fibroblast growth factor receptor (FGFR) inhibitor is a standard post chemotherapy advanced treatment line for metastatic urothelial carcinoma harboring FGFR2/3 genomic alterations. It was approved based on a phase 2 clinical ... ...

    Abstract Background: Erdafitinib, a fibroblast growth factor receptor (FGFR) inhibitor is a standard post chemotherapy advanced treatment line for metastatic urothelial carcinoma harboring FGFR2/3 genomic alterations. It was approved based on a phase 2 clinical trial, revealing a 40% response rate, and 13.8 months overall survival. These FGFR genomic alterations are uncommon. Thus, real-world data on erdafitinb use is scant. We herein describe erdafitinib treatment outcome in a real world patient cohort.
    Methods: We retrospectively reviewed the data of patients treated with erdafitinib from 9 Israeli medical centers.
    Results: Twenty-five patients with metastatic urothelial carcinoma (median age 73, 64% male, 80% with visceral metastases) were treated with erdafitinib between January 2020 to October 2022. A clinical benefit (complete response 12%, partial response 32%, stable disease 12%) was seen in 56%. Median progression-free survival was 2.7 months, and median overall survival 6.73 months. Treatment related toxicity ≥ grade 3 occurred in 52%, and 32% discontinued therapy due to adverse events.
    Conclusions: Erdafitinib therapy is associated with a clinical benefit in the real world setting, and associated with similar toxicity as reported in prospective clinical trials.
    Language English
    Publishing date 2023-05-24
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2023.1151701
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Testicular cancer survivorship: Long-term toxicity and management.

    Shrem, Noa Shani / Wood, Lori / Hamilton, Robert J / Kuhathaas, Kopika / Czaykowski, Piotr / Roberts, Matthew / Matthew, Andrew / Izard, Jason P / Chung, Peter / Nappi, Lucia / Jones, Jennifer / Soulières, Denis / Aprikian, Armen / Power, Nicholas / Canil, Christina

    Canadian Urological Association journal = Journal de l'Association des urologues du Canada

    2022  Volume 16, Issue 8, Page(s) 257–272

    Language English
    Publishing date 2022-07-26
    Publishing country Canada
    Document type Journal Article ; Review
    ZDB-ID 2431403-1
    ISSN 1911-6470
    ISSN 1911-6470
    DOI 10.5489/cuaj.8009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Canadian Urological Association consensus guideline: Management of testicular germ cell cancer.

    Hamilton, Robert J / Canil, Christina / Shrem, Noa Shani / Kuhathaas, Kopika / Jiang, Maria Di / Chung, Peter / North, Scott / Czaykowski, Piotr / Hotte, Sebastien / Winquist, Eric / Kollmannsberger, Christian / Aprikian, Armen / Soulières, Denis / Tyldesley, Scott / So, Alan I / Power, Nicholas / Rendon, Ricardo A / O'Malley, Martin / Wood, Lori

    Canadian Urological Association journal = Journal de l'Association des urologues du Canada

    2022  Volume 16, Issue 6, Page(s) 155–173

    Language English
    Publishing date 2022-05-25
    Publishing country Canada
    Document type Journal Article
    ZDB-ID 2431403-1
    ISSN 1911-6470
    ISSN 1911-6470
    DOI 10.5489/cuaj.7945
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey.

    Alzahrani, Mashari / Clemons, Mark / Sienkiewicz, Marta / Shrem, Noa Shani / McGee, Sharon F / Vandermeer, Lisa / Sehdev, Sandeep / Savard, Marie France / Awan, Arif / Canil, Christina / Hutton, Brian / Pond, Gregory / Saunders, Deanna / Ng, Terry

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

    2021  Volume 29, Issue 11, Page(s) 6903–6912

    Abstract: Background: Optimal use of bone-modifying agent (BMA) therapy in patients with bone metastases from breast and castrate-resistant prostate cancer (CRPC) is evolving.: Methods: Patients receiving BMA for bone metastases from breast or CRPC were ... ...

    Abstract Background: Optimal use of bone-modifying agent (BMA) therapy in patients with bone metastases from breast and castrate-resistant prostate cancer (CRPC) is evolving.
    Methods: Patients receiving BMA for bone metastases from breast or CRPC were surveyed. Information was collected on patient and disease characteristics, BMA treatments and perceptions regarding BMA benefits and side effects. Interest in participation in trials of de-escalated BMA therapy was also gauged.
    Results: Of 220 patients contacted, 172 eligible patients responded (response rate 78%). Median age was 67 (range: 21-91); 137 (80%) had breast cancer and 35 (20%) CRPC. Symptomatic skeletal events (SSEs) occurred prior to starting BMAs in 61% (84/137) of breast and 48% (17/35) of CRPC patients. Among breast cancer patients, 47, 33 and 13% received zoledronate, pamidronate and denosumab, respectively. Eighty-five percent (30/35) of CRPC patients received denosumab. De-escalation of therapy was more common among breast cancer patients. Although most patients correctly reported the goals of BMA therapy were to "help stop fractures" (62%) and "[improve] quality of life" (63%), 46.5% felt it prolonged survival and 54% felt it reduced bone progression. Most respondents (102/129, 79%) were comfortable with de-escalating to 6-monthly treatment after 2 years of BMA therapy. Patients considered the most important endpoints of de-escalation studies to be "stability of bone metastases" (45%), "quality of life" (22%) and "SSE rates" (14%).
    Conclusion: Twelve weekly BMA was more common in breast than in prostate cancer. There remain misconceptions about the benefits of BMAs, highlighting potential gaps in patient education. Patients were interested in further BMA de-escalation after 2 years of prior BMA and provided study endpoints that were most important to them.
    MeSH term(s) Aged ; Bone Density Conservation Agents/therapeutic use ; Bone Neoplasms/drug therapy ; Humans ; Male ; Perception ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Quality of Life ; Surveys and Questionnaires
    Chemical Substances Bone Density Conservation Agents
    Language English
    Publishing date 2021-05-22
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 1134446-5
    ISSN 1433-7339 ; 0941-4355
    ISSN (online) 1433-7339
    ISSN 0941-4355
    DOI 10.1007/s00520-021-06238-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3697: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top